Telix Pharmaceuticals (NASDAQ:TLX) Receives "Sell (D)" Rating from Weiss Ratings

Key Points

• Weiss Ratings has reiterated a "sell (D)" rating for Telix Pharmaceuticals (NASDAQ:TLX), signaling potential concerns about the company's performance.
• Despite the negative rating, Telix Pharmaceuticals' stock saw a 2.9% increase on Wednesday, reaching $10.24, though it remains well below its twelve-month high of $30.36.
• Analysts offer mixed ratings for the stock, with an average target price of $21.00 and a consensus rating of "Moderate Buy".

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "sell (d)" rating reiterated by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

TLX has been the subject of a number of other reports. UBS Group decreased their price objective on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Tuesday, September 23rd. Citigroup started coverage on Telix Pharmaceuticals in a research note on Thursday, September 18th. They set a "buy" rating and a $22.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. Finally, William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $21.00.

Telix Pharmaceuticals Stock Up 2.9%

Shares of Telix Pharmaceuticals stock traded up $0.29 during trading on Wednesday, reaching $10.24. 90,741 shares of the company were exchanged, compared to its average volume of 203,750. Telix Pharmaceuticals has a twelve month low of $8.93 and a twelve month high of $30.36. The business has a 50-day moving average price of $10.61 and a 200-day moving average price of $14.47.

Institutional Trading of Telix Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Private Advisor Group LLC bought a new stake in shares of Telix Pharmaceuticals in the first quarter valued at about $170,000. ABC Arbitrage SA bought a new stake in shares of Telix Pharmaceuticals in the first quarter valued at about $451,000. Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $975,000. Jane Street Group LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $564,000. Finally, IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.